Endogena Therapeutics closed today their first round of Series A financing, which was capped at $8 million. This first round of Series A financing was led by existing investors, Rejuveron Life Sciences AG and DEFTA Partners, with new investors joining the syndicate.

Matthias Steger, CEO of Endogena, said: “This Series A-1 funding will enable us to complete first clinical proof-of-concept studies of our novel treatment paradigm for patients with devastating degenerative eye conditions.” Find out more here.